Skip to main content

Table 1 Patients and tumor characteristics

From: Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

Characteristics

No. of patients

Percent(%)

Age, years

 Median(range)

52(32–71)

 

Menopausal status

 Postmenopausal

21

65.63%

 Premenopausal

11

34.37%

ER

  + 

16

50.00%

 -

16

50.00%

PR

  + 

9

28.13%

 -

23

71.87%

HER2

  +  + 

8

25.00%

  +  +  + 

24

75.00%

Primary and Metastatic sites

 Breast

17

53.13%

 Lung

12

37.50%

 Liver

8

25.00%

 Bone

14

43.75%

 Viscera

25

78.13%

 Lymph node

29

90.63%

  1. Viscera: Liver, lungs, adrenal gland and ovaries